2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatients
2021
Machine Learning–Based Surveillance Strategy after Complete Ablation of Initially Recurrent Hepatocellular Carcinoma: Worth the Risk?
Nam D, Chapiro J. Machine Learning–Based Surveillance Strategy after Complete Ablation of Initially Recurrent Hepatocellular Carcinoma: Worth the Risk? Journal Of Vascular And Interventional Radiology 2021, 32: 1558-1559. PMID: 34717834, DOI: 10.1016/j.jvir.2021.08.014.Peer-Reviewed Original ResearchConceptsRecurrent hepatocellular carcinomaHepatocellular carcinomaComplete ablationSurveillance strategies
2019
Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience
Ekpanyapong S, Philips N, Loza BL, Abt P, Furth EE, Tondon R, Khungar V, Olthoff K, Shaked A, Hoteit MA, Reddy KR. Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience. Journal Of Clinical And Experimental Hepatology 2019, 10: 304-315. PMID: 32655233, PMCID: PMC7335705, DOI: 10.1016/j.jceh.2019.11.003.Peer-Reviewed Original ResearchRecurrent hepatocellular carcinomaLiver transplantationHepatocellular carcinomaHCC recurrenceHCC recurrence post-LTPost-LT HCC recurrenceLarge single-center experienceAccepted therapeutic optionRecurrence post-LTSirolimus-based immunosuppressionSingle-center experiencePredictors of recurrencePredictors of survivalMultiple recurrent lesionsExplant pathologyPost-LTPeritoneal diseasePeritoneal recurrenceInitial recurrenceMedian survivalCenter experienceLow albuminCareful candidate selectionClinical presentationMedian time
2010
Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma
Shin W, Suh K, Lee H, Kim J, Kim T, Yi N, Lee K. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transplantation 2010, 16: 678-684. PMID: 20440777, DOI: 10.1002/lt.22047.Peer-Reviewed Original ResearchConceptsAdult Living Donor Liver TransplantationDonor liver transplantationHepatocellular carcinomaPrognostic factorsLiver transplantationUnresectable diseaseBony metastasesMultiorgan involvementVascular invasionAlpha-fetoprotein level >Multivariate analysisMedian time to recurrenceRecurrent hepatocellular carcinomaTime to recurrenceEarly hepatocellular carcinomaMedian survival timeSurgical resectionRecurrent lesionsGood prognosisShorter survivalAdult patientsUnivariate analysisFollow-upAppropriate treatmentRecurrence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply